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RESUMO 
 
Nos últimos anos, a disfunção mitocondrial e o stresse oxidativo têm sido apontados como 
intervenientes principais no processo neurodegenerativo subjacente a doença de Alzheimer, 
Parkinson, Huntington, Esclerose amiotrófica lateral e mais recentemente, na 
Degenerescência lobar frontotemporal (FTLD).  
A diminuição da actividade dos complexos da cadeia respiratória mitocondrial tem como 
principal consequência o aumento das espécies reactivas de oxigénio e a diminuição da 
produção de ATP pela fosforilação oxidativa, o que leva ao comprometimento de diversos 
processos metabólicos indispensáveis à sobrevivência celular. Deste modo, o conteúdo 
plasmático de ATP poderá ser um bom indicador do défice energético resultante da 
diminuição da função mitocondrial nos tecidos de maior aporte energético, nomeadamente 
no cérebro dos doentes com FTLD. 
Usando um método de bioluminescência, foram analisados os níveis plasmáticos de ATP em 
40 doentes com diagnóstico provável de FTLD, seguidos na Unidade de Neurologia do 
Centro Hospitalar e Universitário de Coimbra, e em 20 indivíduos saudáveis. 
Os resultados obtidos mostram que a concentração plasmática de ATP nos doentes com 
FTLD está significativamente diminuída, relativamente ao grupo controlo, principalmente nos 
doentes com défice cognitivo de acordo com a escala MMSE. A actividade do complexo I da 
cadeia respiratória mitocondrial nos linfócitos destes doentes apresenta uma correlação 
positiva com a concentração plasmática de ATP, o que reflecte uma possível diminuição da 
actividade deste complexo associado a uma menor produção de ATP. Os nossos resultados 
mostram também uma correlação negativa entre o conteúdo plasmático de ATP e a 
atividade da ATP-sintetase nos linfócitos dos doentes com FTLD, reforçando a evidência de 
disfunção mitocondrial e consequente défice energético no processo neurodegenerativo que 
ocorre na FTLD. 
Por outro lado, uma vez que o ATP pode atuar como sinalizador, nomeadamente na 
libertação de glutamato, pode desempenhar um papel importante na desregulação 
neuroquímica que ocorre na neurodegenerescência. 
Os resultados do presente trabalho são originais e adicionam um conjunto significativo de 
dados ao conhecimento dos mecanismos envolvidos na patogénese da FTLD. 
 
Palavras-chave: Degenerescência lobar frontotemporal, ATP, mitocôndria, cadeia 
respiratória mitocondrial, défice energético 
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1. Frontotemporal lobar degeneration 
Frontotemporal lobar degeneration (FTDL) is the second most common type of primary 
degenerative dementia and comprises a spectrum of clinically, pathologically and genetically 
heterogeneous neurodegenerative disorders with often asymmetrical atrophy of the frontal 
and anterior temporal brain lobes [1–3]. 
In 1892, Arnold Pick described the first patient with progressive aphasia and lobar atrophy, 
and later in 1911, Alois Alzheimer reported the presence of argyrophilic neuronal inclusions 
at neuropathological examination, usually known as „Pick bodies‟ [3]. 
Usually, FTLD occurs between 35-75 years and is more common in individuals with a 
positive family history of dementia, although the age of onset in familiar and sporadic cases 
does not differ significantly [4,5]. Several epidemiological studies suggest that men and 
women are equally affected and the duration of illness from onset to death is between 6-8 
years, with a wide range of 2-20 years [5,6]. 
In spite of the difficulty in correlate all clinical symptoms with histopathological hallmarks and 
genetic mutations, some experts have tried to reach a consensus nomenclature for the 
better understanding for physicians and scientists [7,8]. Presently, there are two 
nomenclatures of Frontotemporal lobar degeneration. Some American authors designed 
FTD as a general term for the clinical syndrome (including the behavioural and language 
variants) and the term FTLD is used for all associated pathologies [7]. In other hand, some 
European authors use the term FTLD to both clinical and histopathological characterization, 
whereas they refer to FTD only for the clinical subtype with strong evidence of behavioural 
abnormalities [7]. In the present study, the term FTLD is used to designate all 
histopathological variants (e.g. FTLD-protein) and the term FTD is applied only to 
behavioural variant (bv-FTD) [9]. 
FTLD spectrum can be clinically categorized into three main frontotemporal dementia 
syndromes: (i) behavioural variant (bv-FTD), (ii) semantic dementia (SD), and (iii) progressive 
nonfluent aphasia (PNFA) [1,10]. Some authors include the SD and PNFA in the same 
language variant termed as primary progressive aphasia (PPA) [1]. 
The bv-FTD is mainly characterized by progressive impairment of behaviour, personality 
changes, disinhibition, apathy and diet modifications [11]. On the opposite, patients with 
PNFA have motor speech deficits, characterized by non-fluent and laboured language 
articulation. Other language features such as slow rate of speech, apraxia of speech, anomia, 
agrammatism and impaired word repetition are commonly observed in those patients [1]. 
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Patients with SD have difficulties with the understanding of sentences‟ meaning and lose the 
ability to recognize the significance of faces, objects, and other sensory stimuli [5]. In 
contrast to SD, patients with PNFA have usually preserved social and behavioral function as 
other language features like single-word and object comprehension in the early stage of the 
disease [1]. Despite the first diagnosis of a FTLD patient, it is important to note that, with 
disease evolution, other distinct clinical phenotypes usually start to show overlap, possibly 
reflecting the progressive involvement of other brain regions [12]. 
The most common histopathological hallmarks of FTLD are mainly accumulation of 
microtubule-associated protein tau or/and accumulation of TAR DNA-binding protein (TDP-
43) [7,13]. Tau protein plays a central role in maintaining neuronal integrity and axoplasmic 
transport [7]. In Alzheimer‟s disease (AD) the presence of accumulated tau protein in 
affected tissues has also been detected, and are the major component of the neurofribrillary 
tangles [7]. Tau protein abnormalities result from mutations in MAPT gene, located at 
chromosome 17p21, and are usually associated with FTLD clinical subtypes, such as bv-FTD, 
PNFA, FTLD with Pick‟s bodies, progressive supranuclear palsy (PSP), corticobasal 
degeneration (CBD) and argyrophilic grain disease (AgD) [7,9,13]. 
In the last years, most cases of tau-negative FTLD were thought to have no inclusions, but 
later several studies concluded that some of those cases were immunoreactive for ubiquitin 
and became known as FTLD with ubiquitinated inclusions (FTLD-U). Because almost all 
ubiquitin-positive cases have the presence of mutant TDP-43 protein, FTLD-U has become 
known also as FTLD-TDP [7]. This histopathological phenotype is also associated with 
mutations in progranulin, encoded by PGRN gene, located at chromosome 17q21.32,  and in 
valosin-containing protein, encoded by VCP gene, located at chromosome 9p13.3, [7,13] 
(Figure 1). Nevertheless, some patients with immunoreactive inclusions of ubiquitin but 
TDP-43-negative, have inclusions of fused-in-sarcoma protein (FUS), associated to FUS gene  
(chromosome 16p11.2) mutations, referred as FTLD-FUS [10] (Figre1). Recent studies have 
been demonstrated that a number of patients without TDP-43 pathology, have detectable 
abnormalities in ubiquitin proteasome system (FTLD-UPS) [7]. Additionally, there is also a 
clinical overlap between the FTLD-TDP and mutations in chromosome-9p-linked to Motor 
Neuron Disease, known as FTD-MND [3,5,7] (Figure 1).  
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Figure I - Clinical and histopathological overlap in FTLD. Adapted from [3]. ALS – Lateral amyotrophic 
sclerosis; FTD-MND – Frontotemporal lobar degeneration with Motor Neuron Disease; SD – Semantic 
Dementia; bv-FTD – behavioral variant of FTLD; PNFA – Progressive Non-fluent aphasia; CBD – Corticobasal 
degeneration; PSP – Progressive supranuclear palsy; TDP-43 - DNA-binding protein; TAU – microtubule-
associated protein tau; FUS – fused-in-sarcoma protein. 
 
 
However, despite the advances of immunochemistry techniques, there are several tau-
negative and ubiquitin-negative cases that were considered as dementia lacking distinctive 
histopathology (DLDH), currently referred as FTLD with no known inclusions (FTLD-ni) 
[1,7,9,14]. The presence of neurological abnormalities are usually associated with shorter 
survival of FTLD patients [5]. 
One important source of information about histopathology of associated clinical FTLD 
diagnosis is an inherited mutation in a gene coding for a protein with specific abnormality. 
Recently, the presence of abnormal proteins in biological fluids has conducted to the 
identification of genetic alterations, favoring genotype-phenotype correlation. Accordingly, 
genetic characterization has become an important tool in diagnosis and treatment approach, 
particularly in familial variants of FTLD [15–18]. Approximately 40% of FTLD patients have a 
positive family history of dementia, suggesting a strong genetic hereditary contributing factor 
for this disease; in most cases, there is an autosomal dominant inheritance pattern [1,6]. The 
first-degree relatives of a FTLD patient have 3.5 times more probability to develop dementia 
before 80 years of age when compared to subjects without family history of disease [1].  
The FTLD patients usually show deficiencies in serotonin and dopamine neurotransmitter 
systems, while there is no evidence of impairment of acetylcholinergic and GABAergic 
system [5,19]. However, there has been an increased interest in the glutamatergic system in 
FTLD, since the FDA approval of Memantine, a low to moderate affinity noncompetitive N-
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methyl-D-aspartate (NMDA) receptor antagonist, for treatment of other neurodegenerative 
disease, such as AD and recently also for FTLD [1,19]. Because of the neuroprotective effect 
of Memantine in slowing disease progression of FTLD, the glutamatergic system seems to 
have an important role also in this disease [19]. 
Currently, there is no plausible explanation for selective vulnerability of individual neurons 
and particular populations of neurons, but several factors, such as metabolic activity, 
excitatory amino acid input, numbers and types of excitatory amino acid receptors, Ca2+ 
homeostasis and presence of free-radical scavengers can be crucial to determine the onset 
of disease development [20]. 
Because mitochondria play a central role in so many fundamental metabolic processes for 
cell survival, mitochondrial dysfunction has long been associated as an important marker of 
the pathogenesis of many common age-related neurodegenerative diseases, including 
Alzheimer‟s disease (AD), Parkinson's disease (PD), Huntington's disease (HD), Amyotrophic 
lateral sclerosis (ALS) and recently in FTDL [21–24]. 
  
 Rita Monteiro             6 
 
2. The mitochondrion 
Mitocondria are membrane bound organelles present in all cells of the body (except in 
erythrocytes) and are usually designated as the “powerhouse of the cell” because they are 
responsible for almost all adenosine 5‟-triphosphate (ATP) production [25,26]. Mitochondria 
are maternally inherited and essential to maintaining tissues with high ATP demand healthy, 
as brain and muscle [27]. They are dynamic organelles, which trafficking is critical to their 
strategic intracellular distribution, presumably according to local energy demands [25,28]. In 
neurons, presynaptic terminals, at the ends of axons, and at postsynaptic terminals, at the 
ends of dendrites, where bioenergetic demand is particularly high, are enriched in 
mitochondria [25]. 
The main energy fuel for cellular metabolism is glucose, which is catabolized in three 
processes: glycolysis, tricarboxylic acid cycle (TCA or Krebs cycle) and oxidative 
phosphorylation (OXPHOS) [29,30]. To iniate the glycolysis, mitochondrion needs four 
molecules of ATP and two of NADH, per molecule of glucose [30]. Then, the glucose is 
partially converted through a series of enzyme-catalyzed reactions into two pyruvate 
molecules [30]. Then, Pyruvate is catalyzed by pyruvate dehydrogenase complex into Acetyl-
CoA in the matrix of mitochondrion [29,30]. Later, Acetyl-CoA is catalyzed into NADH, 
FADH2 and CO2 in TCA, that also occurs in the mitochondrion matrix providing reduced 
equivalents to drive OXPHOS in the mitochondrial respiratory chain (MRC) system [30,31]. 
The MRC consists in five complexes (complexes I–V, NADH-coenzyme Q reductase, 
succinate-coenzyme Q reductase, ubiquinol-cytochrome c reductase, cytochrome oxidase 
and ATP synthase, respectively), two mobile electron carriers (ubiquinone/coenzyme Q and 
cytochrome c), all located in the mitochondrial inner membrane (MIM) of mitochondria 
[26,32] (Figure 2). The energy released by NADH and FADH2  oxidation are used to 
generate a proton gradient across MIM that will be used by ATP-synthase to phosphorylate 
ADP and produce ATP, at the same time that protons return to the mitochondrial matrix 
through a channel in complex V [26,33,34].  
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Figure II – Mitochondrial respiratory chain complexes. Adapted from Dudkina et al., 2010 [35]. M- matrix; MIM- 
mitochondrial inner membranne; IMS - intermembrane space. 
The regulation of ATP production by ATP-synthase is determinated by cellular energy 
demand and by other factors, such as intramitochondrial substrate concentration (eg. ADP) 
or Ca2+ levels [36]. An important key parameter for determining energy status of 
mitochondria is the proton-motive force across the inner membrane (∆p) [29]. In the 
presence of physiological concentrations of Pi and Mg
2+, brain mitochondria maintain a total 
∆p of 220mV with a membrane potential between 150-180 mV [37]. All MRC complexes 
have subunits encoded by nuclear and mitochondrial DNA (mtDNA), except complex II, 
wich is exclusively encoded by the nuclear genome [26]. 
In addition to ATP synthesis, mitochondria are also responsible for other important 
regulatory metabolic pathways, such as steroid synthesis, modulation of Ca2+ signaling, amino 
acid biosynthesis, fatty acid oxidation, insulin regulation and cell death [26,28,38,39].  
 
2.1 Mitochondria and cell death 
Mitochondria are also involved in the regulatory process of cell death by necrosis and 
apoptosis [23,34]. In neurons, both of these conditions can either coexist or be sequential 
events depending of the severity of the initiating insult and ATP levels, among other 
factors[23]. 
There are two main apoptotic pathways described in literature: the extrinsic pathway, 
involving the activation of death receptors, and the intrinsic mitochondrial pathway, both 
involving the activation of a caspase cascade [40]. Some stimulus, such as growth factor 
deprivation, ionizing radiation, and several chemical agents can activate the mitochondrial 
pathway of apoptosis inducing cytochrome c release [40]. Characteristic features of 
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apoptosis are condensation of nuclear chromatin and regulated action of catabolic enzymes 
(proteases and nucleases) [41,42]. In contrast, necrosis does not involve any regular DNA 
and protein degradation pattern and is followed by cytoplasm swelling, which occur shortly 
before cell membrane rupture [43]. 
If cell death can occur in two different pathways, depending of the intensity of the initiating 
insult, this suggests the possibility of a downstream event that could control and decide the 
progression of cell death to apoptosis or necrosis [44,45]. Accordingly, individual cell death 
can be decided by available ATP stores originated from OXPHOS and glycolysis. In 
apoptosis, the maintenance of a certain ATP level is needed to initiate cell death, because 
many of these subsequent events are ATP-dependent processes [44]. By contrast, cell death 
by necrosis is associated with low ATP levels and could be initiated by toxic insults, such as 
glutamate excitotoxicity [23]. Thus, ATP levels seem to be an important switch for decision 
between cell death by apoptosis and necrosis in different cellular tissues, including central 
nervous system (CNS) cells (Figure 3) and may contribute to the neurodegeneration process 
in diseases like FTLD. 
 
 
 
 
 
 
 
 
 
 
 
Figure III – Influence of ATP synthesis in type of cell death. In mild cellular energy decrease, there is sufficient 
ATP to induce cascade of apoptosis pathway. When energy impairment is severe, the cell cannot initiate cell 
death through apoptosis and switch to necrosis. From Seppet et al. (2009) [45]. 
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3. Mitochondrial cascade hypothesis for neurodegenerative 
diseases 
The first hypothesis explaining the development of AD derived from the studies that 
emphasize the importance of mutant β-amyloid protein (aβ) deposition, as a consequence of 
mutations in APP gene that codifies the precursor of amyloid protein. This theory became 
known as “amyloid cascade hypothesis” [46]. In Tauopathies (as FTLD-tau and some forms 
of AD), the presence of tangles with aggregated protein tau were thought to be intimately 
related with disease development [47]. However, this hypothesis does not specify what 
initiates the common sporadic form of AD because in almost all cases there is no identifiable 
mutation responsible for the disease development [46,47]. 
To fill this gap, Swerdlow and Khan proposed, in 2004, the “mitochondrial cascade 
hypothesis”, with the intention to build a bridge between the “amyloid cascade hypothesis” 
and the central role of mitochondria in aging and in neurodegenerative process [46,47]. In 
fact, they suggested that inheritance of mitochondrial baseline function can influence how 
mitochondria may change with aging, and AD histopathology and symptoms emerge when 
mitochondria reaches a pathologic threshold [47]. An interaction between a primary genetic 
defect involving energy metabolism and the impairment of mitochondrial function that 
accompanies normal aging and structural changes in MRC complexes, would subsequently 
lead to a decrease in ATP production and possibly to electron leakage, accumulation of toxic 
ROS, and release of apoptotic-inducing factors that would ultimately lead to neuronal loss 
[26,28,48]. According to this idea, Yao et al. showed that mitochondrial dysfunction and 
bioenergetics impairment can occur early in pathogenesis of AD and precede the 
development of observable plaque formation, in a mouse AD model [20].  
During normal embryogenesis, reduced cell energy promotes physiologically tau 
phosphorylation. Repeated cell division in normal embryogenesis uses considerable high 
quantities of cell energy and energy storage is not possible during this phase. Mitochondrial 
cascade hypothesis also suggest that a similar mechanism can occur in neurodegenerative 
diseases with presence of histopathological hallmark of tau protein [47]. 
Thus, impaired mitochondrial function is one possible mechanism responsible for 
bioenergetic failure and some cell demise consequences in neurodegenerative diseases as 
FTLD [2]. 
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4. Mitochondrial dysfunction in neurodegenerative diseases 
It is widely recognized that there is a decline of basal metabolic function of mitochondria and 
MRC activity becomes less eficient during aging. There are evidences that old mitochondria 
are morphologically altered and functionally produce more ROS and less ATP [49]. The 
complexes I and IV activity seems to be the most affected by aging process; in contrast, the 
activity of complexes II and III appear to be the most preserved [49]. 
There are few studies evidentiating an impairment of MRC activity in neurons and other 
periphery tissues in FTLD [50]. However, FTLD pathology is similar in some points with AD 
and other neurodegenerative diseases, such as PD, HD and ALS [51].  
In AD, there are previous studies showing decreased activity of MRC complexes I, III and IV 
in neurons, platelets and lymphocytes from blood samples and posmorten brain tissue 
[24,26,49,52]. Cardoso et al. (2004) showed a deficiency in cytochrome c oxidase (COX, 
complex IV) activity in AD platelets [53]. These results were consistent with the study of 
Bosetti et al. (2002) that have previously reported a decreased COX activity in human 
platelets and in brain tissue samples from hippocampus [54].  
In tauopathies, Schulz et al. (2012) demonstrated a substancial complex I deficiency followed  
by a decrease in mitochondrial ATP production [50,55]. Complex I is an important target for 
ROS and abnormal activity of this complex usually leads to more ROS production and 
disturbance of the mitochondrial membrane potential, m [56]. In fact, there are evidences 
in literature that reduced activity of one or more OXPHOS enzymes can compromise ATP 
synthesis and further increase ROS production, which often causes structural and functional 
cell membrane alterations and, in the limit, leading to neuronal death [53].  
Although, MRC is not the only system in mitochondria that is affected in neurodegenerative 
diseases, an altered activity of OXPHOS enzymes had also been reported [45]. For example, 
there are evidences of reduced activity of pyruvate dehydrogenase and ketoglutarate 
dehydrogenase complexes in AD neurons [47]. 
Moreover, published data support the idea that mitochondrial enzyme impairments in AD 
brain are reflected in peripheral tissues, particularly in platelets, fibroblasts, as well as in 
lymphocytes [52–54]. Additionally, a complex I reduced activity has been reported in a FTLD 
patient [2]. 
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5. Energy impairment and excitotoxicity 
In the last decades, a close association between the energy state of nervous cells and 
glutamate neurotoxicity has been suggested [57]. As previously mentioned, the glutamatergic 
system also seems to have an important role in FTLD [19]. 
Glutamate is the most abundant excitatory amino acid neurotransmitter in the brain and 
plays a proeminet role in fast synaptic plasticity and in important cognitive functions like 
learning and memory [58]. Moreover, glutamate can serve as an alternative energy supplier 
in the absence of glucose in neurons [58,59]. 
Neurotoxicity-evoked by glutamate, designed as “excitotoxicity”, has been implicated in 
neurodegeneration linked to pathological conditions, associated with failure of energy 
metabolism, such as brain ischemia, hypoglycemia and cerebral trauma, as well as, with some 
chronic neurodegenerative diseases such as Alzheimer‟s disease, Huntington‟s disease, 
Parkinson‟s disease and amyotrophic lateral sclerosis [57,58,60,61].  
The toxic effects of glutamate was first observed at 1957 by Lucas and Newhouse in 
degeneration of retinal cells after exposure to noxious concentrations of glutamate [62]. 
Olney and co-workers in 1969, coined the term “excitotoxicity” when described the 
intracranial brain lesions in response to subcutaneous injections of glutamate in infant and 
adult mice [63].  
Glutamate receptors can be divided in two major groups: metabotropic and ionotropic 
receptors [58]. Ionotropic receptors include N-methyl-D-aspartate (NMDA) receptors, 2-
amino-3-(3-hydroxy-5-methylisoxazol-4-yl) propionate (AMPA) receptors and kainate 
receptors [64]. Under physiological conditions, glutamate is released from glutamatergic 
nerve terminals and causes depolarization of post-synaptic receptors, leading to Mg2+ release 
from NMDA receptor channel and allowing  Ca2+ influx into cytosol [58,65]. 
The excitotoxic neuron injury can be the consequence of direct or indirect pathways, and 
both have the same finishing course to induce cell death. In the direct pathway, glutamate 
transporters are also altered in both quantity and structure, and there is a less effective 
process in removing glutamate from the extracellular space [66]. This results in increased 
concentration of glutamate in postsynaptic receptors and it remains for longer periods [66]. 
Prolonged activation of NMDA receptors leads to a number of deleterious consequences, 
such as impairment of intracelular calcium buffering, ROS production and activation of the 
mitochondrial permeability transition pore (MPTP) and ultimately in neuronal death [39,58]. 
In indirect excitotoxic pathway, a primary bioenergetic impairment causes non-toxic 
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glutamate levels to become lethal and causing membrane depolarization of the pos-synaptic 
terminals and excessive Ca2+ influx through NMDA receptors [58]. According to this 
hypothesis, Del Rio et al. (2007) proved that an increase of extracellular concentration of 
glutamate does not cause neuronal death, unless impairment of energy metabolism occurs 
simultaneously with a severe decrease in cytosolic ATP levels [57].  
One of the primary physiologic functions of Ca2+ in mitochondria is stimulation of OXPHOS 
and ATP production [39]. Neurons can control intracellular Ca2+ levels through a complex 
interplay between Ca2+ influx, Ca2+ efflux, Ca2+ buffering, and internal Ca2+ storage [64]. 
Moreover, Ca2+ inside mitochondria regulates several important biological mechanisms, such 
like allosteric activation of pyruvate dehydrogenase, isocitrate dehydrogenase, and α-
ketoglutarate dehydrogenase, as well as stimulation of ATP synthase (complex V) activity 
[39]. When intracellular Ca2+ concentrations increase, mitochondria can buffer the excess of 
Ca2+ through a sodium-calcium exchanger into mitochondrial stores, that results in decrease 
of mitochondrial membrane permeability, increasing ROS generation and, consequently, 
enhance mtDNA mutations that results in a decline of OXPHOS activity [59]. 
This excitotoxic process can be divided into three phases of cytoplasmatic Ca2+ elevation: 
the initial peak  after exposure of glutamate, a subsequent plateau and after the begining of 
the “delayed Ca2+ deregulation” phase, when the continued presence of glutamate is not 
obligatory and which culminates in the irreversible failure of cytoplasmic Ca2+ homeostasis 
[67]. These excessive influx of Ca2+, via NMDA receptors, attenuates the m∆Ψ, and leads to 
the opening of the MPTP and initiates cell death cascade by apoptosis [39,68]. 
From these evidences, mitochondrial Ca2+ loading seems to be one critical step in acute 
glutamate excitotoxicity and several experiments have been done for therapeutic aproaches 
in blocking NMDA recptors or in removing Ca2+ from the cytosol of the affected neurons 
[64,65,68]. Presently, there are some NMDA receptors antagonists that are intended to 
modulate glutamatergic function and reduce neuronal death induced by excitotoxicity in 
some neurodegenerative disorders, such as AD  [60,65]. Nonetheless, NMDA receptors 
antagonists had not proven clinically the most wanted treatment effects, and new approaches 
have been designed to avoid glutamate exposure by reduce circulating glutamate levels in the 
blood and consequently lowering glutamate concentrations in the brain [58].  
In conclusion, mitochondrial dysfunction, energy impairment and excitotoxic neuronal injury 
seems to be one common point among different neurodegenerative diseases, such as AD, 
PD, ALS and FTLD, that, in the end, share the same cell fate, with different but similar 
implicated neuropathological mechanisms. 
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Massive extracellular release of ATP has been associated with metabolic stress, brain 
ischemia and trauma, which make purinergic system an important mechanism in 
neurodegeneration aetiopathology [69].   
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6. Extracellular ATP 
Adenosine 5'-triphosphate (ATP) is a nucleotide found in cytosol of every cell, and is the 
major energy source for maintenance of cell survival, especially in the brain, because neurons 
are cells wih a high energy demand [24]. 
On the other hand, some properties of ATP make it an ideal molecule for cell–cell signaling: 
it is a small, rapidly diffusing molecule, highly unstable and not abundant in the extracellular 
environment [69,70]. In fact, extracellular ATP has been involved in a wide range of 
physiological processes, such as neurotransmission, smooth muscle contraction, endocrine 
secretion, vasodilation and more complex processes, such as immune cell regulation and 
neuroinflammation, pain, modulation of cell proliferation, differentiation and death, 
regeneration, male reproduction, fertilization and embryonic development [69]. 
Virtually, every type of eukaryotic cell can release ATP, and in most of them the intracellular 
ATP concentration are in the milimolar range (3-10 mM) [71,72]. Although, in the 
extracellular environment, ATP concentration is considerably lower (20-100nM) [72].  
Extracellular ATP acts alone as a neurotransmitter, neuromodulator or growth factor, or is 
co-released with acetylcholine, noradrenaline, GABA and glutamate in CNS cells [73,74]. It 
has also been identified as an autocrine/paracrine signal modulator by activation of purinergic 
receptors in the plasma membrane of the exocrine cell and neighborhood cells 
[69,70,75,76].  
There are several purinergic receptors with different actions (Table 1). The P1 receptors 
also belong to the purinergic receptor family but its main agonist is adenosine, not ATP [73]. 
The P2 receptors were divided into P2X and P2Y receptors due to their pharmacologic and 
molecular cloning properties. Currently, there are 7 subtypes of ionotropic P2X receptors 
(P2X1, P2X2, P2X3, P2X4, P2X5, P2X6 and P2X7) and 8 subtypes of metabotropic P2Y 
receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14) known [72,77]. 
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Table A 
Endogenous agonist of purinergic P2X and P2Y receptors and its distribution in the human body. Adapted from 
Burnstock et al. (2006) and Abbracchio et al. (2009) [73,74].   
 
 
The P2X receptors are called “fast receptors” because are transmitter-gated cation channels 
and act within milliseconds when ligand bind and consequently open the ion channel. As a 
consequence of their properties and relatively low affinity for ATP (in the µM range), P2X 
receptors mediate fast ATP signaling over short distances, for example, in response to the 
release of ATP from a synaptic vesicle [76]. By contrast, P2Y receptors are stimulated at low 
concentrations of ATP (nM range), and ATP binding triggers second-messenger cascades that 
amplify and prolong signal duration [76]. These receptors have neuromodulatory functions 
because they can detect lower ATP concentrations over longer distances from the release 
site [76]. In nervous system, P2 receptors are widely expressed both in neurons and in cells 
involved in neuroinflammatory responses, such as astrocytes and microglial cells [69]. 
P2X Endogenous agonist:  ATP  
P2X1  Smooth muscle, platelets, cerebellum, dorsal horn spinal neurons 
P2X2  Smooth muscle, CNS, retina, chromaffin cells, autonomic and 
P2X3  Sensory neurons, NTS, some sympathetic neurons 
P2X4  CNS, testis, colon 
P2X5  Proliferating cells in skin, gut, bladder, thymus, spinal cord 
P2X6  CNS, motor neurons in spinal cord 
P2X7  Apoptotic cells in, for example, immune cells, pancreas, skin 
P2Y 
Endogenous agonists:  ATP, ADP, UTP, UDP, NAD+ 
P2Y1 Epithelial and endothelial cells, platelets, immune cells, osteoclasts 
P2Y2 Immune cells, epithelial and endothelial cells, kidney tubules, osteoblasts 
P2Y4 Endothelial cells 
P2Y6 Some epithelial cells, placenta, T cells, thymus 
P2Y11 Spleen, intestine, granulocytes 
P2Y12 Platelets, glial cells 
P2Y13 Spleen, brain, lymph nodes, bone marrow 
P2Y14 Placenta, adipose tissue, stomach, intestine, discrete brain regions 
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Moreover, a number of physiological and pathophysiological stimuli including ischemia, 
hypoxia, platelet aggregation, sympathetic nerve stimulation and cell damage, can lead to an 
increase in extracellular ATP concentration, despite the strict control exerted by 
ectonucleotidases, which act to maintain ATP and its metabolites (AMP and ADP) in low 
physiological concentrations [69,78,79]. The extracellular ATP is hydrolyzed by 
ectonucleotidases CD39, which converts ATP and ADP to adenosine monophosphate 
(AMP), and CD73, which converts AMP to adenosine [71,72]. The nucleotide-degrading 
system also plays an essential role in the purinergic signaling because ATP hydrolysis 
generates adenosine, which is also a powerful modulator of cell functions by activation of P1 
receptors [72]. Then, extracellular ATP concentration can change as a consequence of 
enhanced ATP release, as well as of reduced ATP hydrolysis [72]. 
 
 
6.1 Extracellular ATP and neurodegeneration 
The existence of important physiological extracellular functions of ATP, such as cell 
differentiation and growth, embryonic development and neurogenesis, suggests that an 
imbalance of this homeostasis may be associated with several human diseases, like 
neurodegenerative disorders, immune-mediated inflammatory dysfunction and tumors [69].  
In brain, ATP can be massively released from damaged cells during some pathological 
conditions. Consequently, high extracellular levels of ATP can promote the inflammatory 
process mediated by microglial cells in consequence of a pathological insult. Microglial 
activation results in release of immunoregulatory substances, including cytokines or 
chemokines, or even neurotoxic molecules, such as nitric oxide (NO) and ROS, which will 
contribute to the development of an acute or chronic associated inflammatory reaction [69]. 
In addition, Feuvre et al. (2002) showed that extracellular ATP induces the processing and 
release of interleukin-1β by activation of P2X7 receptors [80]. Cells with exacerbated 
inflammatory mediators are particularly susceptible to the toxic actions of excessive ATP, 
because activation of P2X7 receptors leads to selective activation of nuclear factor kB (NF-
kB), in microglial cells, that enhance expression of NF-kB dependent genes, such as 
interferons and citokines, and activation of other cell death related genes [80]. These results 
have been proposed P2X7 receptors as important mediators in inflammation during 
neurodegeneration. 
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There are also some evidence of a synergism between P2 receptor modulation and 
glutamate-induced excitotoxicity and apoptotic cell death. Some P2 receptors are associated 
with exacerbation of neurotoxic effect induced by glutamate exposure in neurons [69]. For 
all this, P2Y receptors antagonists have been proposed as potential neuroprotective agents 
for neuronal death associated with several neurodegenerative conditions [77]. 
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ABSTRACT 
 
In the last years, mitochondrial dysfunction and oxidative damage have been pointed as 
major contributors to neuronal loss in several neurodegenerative disorders, such as 
Alzheimer's, Parkinson‟s and Huntington's diseases, Amyotrophic Lateral Sclerosis and, more 
recently, in Frontotemporal Lobar Degeneration (FTLD). The decreased activity of 
mitochondrial respiratory chain complexes will enhance ROS production and leads to a 
decline in ATP production, compromising important dependent processes to cell 
maintenance and survival. Accordingly, we hypothesize that plasma ATP levels may be an 
indicator of the mitochondrial activity disturbance in tissues with high ATP demand, such as 
brain, possibly reflecting the energy impairment in the FTLD associated pathology.  
The plasma ATP concentrations of 40 patients with probable diagnosis of FTLD followed in 
the Neurology Unit of the Centro Hospitalar e Universitário de Coimbra were determined 
using a bioluminescence technique and compared to an age-matched control group of 20 
healthy subjects. Our results showed that plasma ATP concentrations in FTLD patients are 
significantly decreased compared to controls, particularly in patients with cognitive 
impairment, according to MMSE scale evaluation. The activity of complex I in lymphocytes 
had a positive correlation with plasma ATP concentration in FTLD patients. Moreover, our 
results showed a negative correlation between the activity of ATP-synthase in lymphocytes 
and plasma ATP levels. These findings provide more evidence of low ATP production due to 
mitochondrial impaired activity in FTLD neurodegeneration. Additionally, since ATP may act 
as a signaling molecule, namely in glutamate release, it may play a role in neurochemical 
impairment occurring in neurodegeneration. These results are original and add a significant 
amount of data to the knowledge of mechanisms involved in FTLD pathogenesis. 
 
Keywords: Frontotemporal lobar degeneration, ATP, mitochondria, mitochondrial 
respiratory chain, energy impairment 
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1. Introduction 
Frontotemporal lobar degeneration (FTLD) is the second most common form of early 
onset-dementia, after Alzheimer disease (AD) [2,10]. This neurodegenerative condition 
usually occurs between 35-75 years of age and is characterized by gradual and progressive 
changes in behaviour, personality and different types of language impairment with 
concomitant atrophy of the frontal and anterior temporal brain lobes [1,4,8,14]. The FTLD 
spectrum can be clinically divided into three main subtypes: behavioural variant (bv-FTD), 
Semantic Dementia (SD) and Progressive Nonfluent Aphasia (PNFA) [1,11,12]. Some 
authors include the SD and PNFA in the same language variant termed as primary 
progressive aphasia (PPA) [1]. There is also a significant clinical overlap with motor neuron 
disease (FTD-MND), as well as, with parkinsonian syndromes, progressive supranuclear palsy 
and corticobasal degeneration [3,5]. The principal hallmarks of FTLD histopathology are 
inclusions of abnormal protein Tau and disturbances in ubiquitin system, whereas there are 
some patients without abnormal protein inclusions and identified gene mutations [7,12,13]. 
Some evidence from epidemiological studies revealed that presence of neurological 
abnormalities are usually associated with shorter survival of FTLD patients [5]. An important 
source of information about histopathology of associated clinical FTLD diagnosis is an 
inherited mutation in a chromosome coding for a protein with the specific abnormality, 
favouring the genotype-phenotype correlation, particularly in familiar forms of FTLD [6].  
The FTLD aetiology is complex and the absence of information about an associated 
pathologic mutation in some sporadic cases, raises other possible explanations for the 
primary event capable of triggering the neuropathologic process. In the last years, some of 
the proposed explanations considered mitochondria as a central player in neurodegenerative 
process and in 2004, Swerdlow and Khan proposed the “mitochondrial cascade hypothesis” 
suggesting that an inheritance of mitochondrial baseline function can influence how 
mitochondria may change with aging and when they will reach a pathologic threshold 
[22,46,52,81]. A possible interaction between a primary genetic defect involving energy 
metabolism and a decline in mitochondrial function that accompanies normal aging, can 
consequently leads to abnormal activity of OXPHOS complexes, a decline in ATP 
production, accumulation of toxic ROS that would ultimately lead to neuronal loss [47,82]. 
In accordance, some previous studies demonstrated that mitochondrial dysfunction 
accompanied by energy impairment can precede plaque formation in AD neurons [20]. Then, 
impairment of mitochondrial activity is associated with the pathogenesis of many common 
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age-related neurodegenerative diseases, such as AD, Parkinson‟s disease, Huntington‟s 
diseases, Amyotrophic lateral sclerosis and, recently in FTLD [26,48,49,83,84].  
The activity of mitochondrial respiratory chain (MRC) complexes I, III and IV seems to be 
the most affected in neurons, platelets and lymphocytes of AD patients [53,54]. In 
tauopathies (as FTLD-tau and some variants of AD), a substantial complex I deficiency with 
concomitant decrease of ATP production has also been reported [50].  
Furthermore, mitochondria are involved in the regulatory process of cell death by necrosis 
and apoptosis. In neurons both these conditions can either coexist or be sequential events 
depending of the initiating insult [23,40,45]. If cell death can occur in two different pathways, 
this suggests that a downstream event could control and decide the evolution of cell death 
[23,45]. Some studies evidentiate that bioenergetic failure resulted by impairment of 
OXPHOS activity seems to be an important switch in decision between these two 
mechanisms of cell death, since in apoptosis, several subsequent events are ATP-dependent 
processes [44,45]. Moreover, this energy deficit can leads to other deleterious consequences 
and compromise some metabolic pathways indispensable to cell survival, particularly in 
neurons, which are cells with high ATP demands [67,85]. In addition, energy deficit has also 
been associated with an exacerbation of glutamate-induced neurotoxicity [37,57,59,65]. 
Extracellular ATP has been involved in a wide range of physiological processes, such as 
neurotransmission. Massive extracellular release of ATP has been associated with metabolic 
stress, brain ischemia and trauma, which make purinergic system an important mechanism in 
neurodegeneration aetiopathology [69]. Extracellular ATP may also act as a 
neurotransmitter, neuromodulator or growth factor, or being co-released with 
acetylcholine, noradrenaline, GABA and glutamate in CNS cells [73,74]. It has also been 
identified as an autocrine/paracrine signal modulator by activation of purinergic receptors in 
the plasma membrane of the exocrine cell and neighborhood cells [69,70,75,76]. 
For all this, mitochondrial dysfunction and impaired energy metabolism seems to be one 
common point among several neurodegenerative disorders, including FTLD, that in the end 
shares the same cell fate, with different, but similar implicated neuropathological mechanisms 
[58,60]. An increased body of evidence supports the idea that these mitochondrial enzyme 
impairments in neurons are reflected in periphery tissues, particularly in platelets and 
fibroblasts, as well as, in lymphocytes of these patients [52–54]. Accordingly, in this study we 
aimed to investigate if plasma ATP concentrations can traduce the neuronal energetic 
depression that possibly may be present in FTLD and if it is related with mitochondrial 
activity in lymphocytes of these patients. 
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Materials and methods 
2.1 Patients and control subjects 
Participation of patients and control subjects was approved by the Institutional Review Board 
of the Centro Hospitalar e Universitário de Coimbra and all patients or their legal 
representatives signed the informed consent to participate. The 40 included patients (17 
females and 23 males; age range: 38-84 years old, mean 67 ± 10) with probable diagnosis of 
FTLD according to the standard criteria of DMS-IV, had been followed at the Neurology 
Unit of the Centro Hospitalar e Universitário de Coimbra [86]. All patients was submitted 
to an evaluation of cognitive impairment by Mini Mental State Examination (MMSE) and 
global dementia severity by Clinical Dementia Rating (CDR) scale, among other clinical 
batteries [87–92]. The MMSE scale (range 0-30) indicates the current severity of cognitive 
impairment [93]. The results obtained with MMSE scale was adjusted according to years of 
scholarity for a total score of 0 and 1 (MMSE 0 – absence of cognitive impairment; MMSE 1 – 
presence of cognitive impairment). Patients‟ group concerns 18 patients with MMSE 0 and 21 
patients with MMSE 1 evaluation (Table 1).  
The CDR scale is between 0 and 3, where “CDR 0” indicates no impairment and CDR 0.5, 
1, 2 and 3 indicate questionable, mild, moderate and severe dementia, respectively [89]. Our 
patient group included 6 patients with “CDR 0.5”, 22 with “CDR 1”, 8 with “CDR 2” and 3 
with “CDR 3” (Table 1). For statistical analysis, we considered early-onset patient group 
when FTLD diagnosis was performed before 65 years and the late-onset after 65 years 
according published references [10,94–97]. 
Twenty healthy age-matched control subjects free of progressive neurological disorders (14 
female and 6 males; age range: 37-80 years old, mean 63 ± 13), were randomly recruited also 
at Neurology Unit of the Centro Hospitalar e Universitário de Coimbra.  
 
2.2  Isolation of lymphocytes and plasma  
Venous blood from FTLD patients and controls was collected into tubes containing K3EDTA 
as anticoagulant. First, the blood sample was diluted (1:1) with Phosphate-Buffered Saline 
(PBS), pH 7.4 and carefully layered on Ficoll-Paque™ before centrifugation. The lymphocytes 
interface layer was collected and washed with PBS and centrifuged again. The cellular pellet 
was suspended into 50-200 µl of PBS and stored in liquid nitrogen, for further MRC 
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enzymatic activities evaluation. Plasma was collected from upper layer after centrifugation 
and was stored at -80ºC until analysis of ATP concentration. 
 
2.3  Measurement of MRC complexes activities 
The MRC complexes I, II, III, IV and V activities were evaluated as previously described 
[98,99], at 37ºC and using a dual wavelength spectrophotometer (SLM AMINCO DW-
2000TM, SLM Instruments). The results were expressed as nmol/min/mg of protein 
normalized to Citrate Synthase (CS) activity, used as a reference of mitochondrial number 
[53,54,98].  
 
2.4 Analysis of plasma ATP concentration 
Plasma ATP was measured using a firefly bioluminescence assay (ATP Bioluminescence Assay 
Kit CLS II: Roche Diagnostics) by luminometry (Berthold FB12 Luminometer), and following 
the manufacturer‟s instructions. In the presence of  substrate D-luciferin, Mg2+, molecular 
oxygen and ATP, Luciferase catalyses a multistep reaction [72,100], according to the 
reaction: 
 
ATP + D-luciferin + O2 → oxyluciferin + PPi + AMP + CO2 + light (λ max=560 nm) 
 
The ATP concentration was determined by measuring the light produced in the reaction and 
the results were expressed in Relative Light Units (RLU‟s) [79]. Every ATP measurement of 
each sample was performed at least in triplicate. 
 
2.5 Correction for haemolysis in plasma samples 
There is evidence in the literature that haemoglobin (Hb) content can influence the 
measurement of plasma adenine nucleotides, including ATP, even at low concentrations 
[79,101]. Accordingly, we had determined the Hb concentrations for all plasma samples of 
the FTLD patients and control subjects, used to estimate the degree of sample haemolysis. 
Plasma Hb concentration was measured using Drabkin‟s method, by spectrophotometry (λ 
max= 540 nm) [102] and every sample was analysed in triplicates. In order to determine the 
correlation between Hb concentration and RLU‟s values, we evaluated the Hb content and 
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ATP level in seven  lysates of blood samples enriched in erythrocytes, as previously  
described by Gorman et al. (2007) [79,101] with slight modifications (appropriated dilutions 
and without stabilizing solution).  
 
2.6 Determination of protein content 
Plasma protein concentration was determined by the Bradford method, as previously 
described [103]. The protein content was measured by spectrophotometry (λ max= 595 nm) 
at least in triplicate for each sample [103].  
 
2.7 Statistical analysis 
The different data groups analysed were compared by a nonparametric Mann–Whitney test 
(two-tailed). To quantify the degree of MRC complexes activities were related to the plasma 
ATP concentrations, we have used a correlation analysis of Spearman. The best-fit line was 
achieved by linear regression. All the statistical tests were evaluated using Software 
GraphPad Prism® 5 considering the p-value < 0.05 as statistically significant [104]. 
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2. Results 
3.1  Adjust of plasma ATP concentration with correction for haemolysis 
To determine the ATP concentration attributable to haemolysis we performed the 
evaluation of haemoglobin content in seven aliquots with different solutions of the same 
supernatant used for ATP determination. The obtained values were correlated by a linear 
regression (y=1,315x) and extrapolated to all ATP and Hb plasma concentration 
measurements of each patient and control subject (Figure1). All the values of plasma ATP 
concentration are presented with correction for haemolysis. 
 
 
 
 
 
 
Figure1– Correlation between ATP concentration and haemoglobin content in plasma. 
 [Hb] – Haemoglobin concentration 
 
3.2  Plasma ATP levels and probable diagnosis 
Our results show decreased plasma ATP levels in FTLD patients (n=40) comparatively to an 
aged-matched control group (p=0.0124) (Figure 2). The majority of FTLD patients had 
probable diagnosis of bv-FTD (n=35) and the statistical analysis showed significant difference 
between these group (p=0.0161) and controls (Figure 2). Patients with other FTLD variants 
(APP and CBD) were not included in the statistical analysis, because the number was too 
small to conclude a correct interpretation (Table I). 
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Figure 2 – Extracellular ATP levels in FTLD and healthy age-matched control subjects. The bv-FTD patient 
group include the familiar variant. The differences between control group and FTLD patients or bv-FTD 
patients are both statistically significant (p=0.0124 and p=0.0161, respectively). The traces represent from top 
to the bottom, upper quartile (Q3), median and lower quartile (Q1) values for each group. CH - corrected for 
haemolysis. 
 
 
3.3 Plasma ATP levels and MMSE scale evaluation 
All FTLD patients were organized in two groups categorized with absence or presence of 
cognitive deficit, corresponding to total scores of 0 and 1 of the MMSE adjusted scale, 
respectively. The results show that patients‟ group with cognitive impairment have 
significantly lower ATP plasma levels, compared to controls (p=0.0026) (Figure 3) (Table 1). 
There are no significant differences in ATP levels between control group and patients with 
MMSE 0 (p=0.1248) and between both patients‟ groups (p=0.1468) (Figure 3). 
 
 
 
 
 
 
Figure 3 – Plasma ATP concentration according to cognitive impairment score. The difference between the 
control group and MMSE 1 patients is statistically significant (p=0.0026). The traces represent from top to the 
bottom, upper quartile (Q3), median and lower quartile (Q1) values for each group. CH- corrected for 
haemolysis. 
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3.4 Plasma ATP levels and CDR scale evaluation 
The analysis of ATP levels according dementia severity using the CDR evaluation for each 
FTLD patient was also performed. The FTLD patients with “CDR 1” (mild dementia) and 
“CDR 2” (moderate dementia) were the lowest ATP values (p=0.0043 and p=0.0307, 
respectively) compared to control group (Table 1). However, patients with “CDR 3” (severe 
dementia) were not included in the statistical analysis because the number was too small for 
a correct interpretation (Table 1).  
 
3.5  Plasma ATP content according to disease duration 
Considering duration of disease (years), there is a statistical significant difference between 
each of the two defined groups of patients and the control group (p=0.0037 and p=0.0225 
respectively) (Figure 4). However, there is no significant difference between both patients‟ 
groups (Figure 4). 
 
 
 
 
 
 
 
 
Figure 4 – Plasma ATP concentration according to duration of disease (years).The difference between both 
patients‟ groups and controls is statistically significant (p=0.0037 for disease duration ≤ 4 years; p=0.0225 for 
disease duration > 4 years). The traces represent from top to the bottom, upper quartile (Q3), median and 
lower quartile (Q1) values for each group. CH - corrected for haemolysis. 
 
 
3.6 Influence of age of onset in plasma ATP content 
The ATP levels of all patients were also evaluated in order to age of onset, and the results 
obtained showed a statistical significant difference between patients with age of onset before 
65 years (p=0.0098) and after 65 years (p=0.0044), versus the control group (Table 1). 
However, there is no significant difference between both patients‟ groups (p=0.3001). 
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3.7  Plasma ATP levels and gender  
The gender distribution, showed that FTLD female group had the lowest ATP values 
compared to the control female group (p=0.0276). However, there is no difference for male 
gender (Figure 5).  
 
 
 
 
 
 
 
 
 
Figure 5- Extracellular ATP levels in FTLD patients and healthy age-matched control subjects according to 
gender. The difference between the female patient and control groups is statistically significant (p=0.0276). The 
traces represent from top to the bottom, upper quartile (Q3), median and lower quartile (Q1) values for each 
group. CH- corrected for haemolysis. 
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Controls   20 1.442 1.283 1.246 5.070 0.034 
 Gender        
  Female 14 1.317 1.240 1.016 5.070 0.053 
  Male 6 1.734 1.334 1.850 3.747 0.034 
FTLD 
patients 
  40 1.472 2.949 0.160 13.340 0.001 
 Gender        
  Female 17 1.808 3.722 0.121 13.340 0.011 
  Male 23 1.223 2.177 0.219 9.011 0.001 
 Diagnosis        
  bv-FTDa 27 1.566 3.163 0.149 13.340 0.001 
  
Familiar 
bv-FTDb 
8 1.460 2.765 0.230 8.663 0.016 
  
Other 
variants 
4 0.108 0.048 0.108 0.174 0.040 
 
MMSE 
evaluation 
       
  MMSE 0 18 2.262 3.916 0.229 13.340 0.011 
  MMSE 1 21 0.651 1.338 0.096 5.960 0.001 
 
CDR 
evaluation 
       
  CDR 0.5 6 3.276 4.902 0.317 13.340 0.023 
  CDR 1 22 1.094 2.506 0.114 9.011 0.011 
  CDR 2 8 0.555 0.663 0.097 1.520 0.001 
  CDR 3 3 2.076 2.747 0.174 5.960 0.094 
 
Disease 
duration 
       
  ≤ 4 years 31 1.068 2.298 0.152 9.011 0.001 
  > 4 years 6 0.330 0.470 0.135 1.373 0.027 
 Age of onset        
  ≤ 65 years 22 1.013 2.108 0.161 9.011 0.016 
  > 65 years 15 0.855 2.157 0.107 8.663 0.001 
Table 1 
Plasma ATP values in controls, according to gender, and in patients according to gender, clinical variant, MMSE 
and CDR scores, age of onset and disease duration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Some patients‟ clinical information was not available: 1 FTLD variant diagnosis, 1 for MMSE 
and CDR criteria, 3 for age of onset and disease duration. a include the familial variant of 
bv-FTD. b Other variants include APP and CDB. 
 Rita Monteiro             31 
 
3.8  Plasma ATP content versus MRC activity in lymphocytes 
Our results showed a positive correlation between ATP values and activities of complexes I 
(p=0.0149, Spearman r = 0.3822) in lymphocytes of FTLD patients (Figure 6, A). However, 
the statistical analysis showed no correlation in activities of complexes II, III and IV and 
plasma ATP content of these patients (Figure 6, B-D). On the other hand, a diminished 
activity of complex V correlated with plasma ATP content of each patient was also observed 
(p=0.0002, Spearman r = -0.5544) (Figure 6, E). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 – Correlation between plasma ATP content and MRC complexes activities of FTLD patients. A – 
Complex I activity/CS; B – Complex II activity/CS; C- Complex III activity/CS; D- Complex IV activity/CS; E – 
Complex V activity/CS. CH- corrected for haemolysis; CS – citrate synthase. 
C 
B 
D 
E 
A 
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3. Discussion 
In the present study, it was aimed to evaluate the involvement of ATP content and its 
correlation with MRC activity in neurodegeneration occurring in Frontotemporal lobar 
degeneration. We measured the plasma ATP content in 40 patients with probable diagnosis 
of FTLD and in 20 healthy age-matched controls.  
As previously described by Gorman et al. (2007) [79,101], haemolysis could play an 
important influence on plasma ATP concentration that must be taken into account for ATP 
measurement. Accordingly, this aspect has been analysed in the present study and the 
obtained mean value of haemolysis percentage was 3.5 ± 1.1 (mean ± SEM) for the 
population in study, indicating that ATP concentration attributable to erythrocytes lysis in 
plasma samples is a minor variable. However, in order to avoid associated error, all ATP 
concentration values were corrected for haemolysis.  
The ATP values were studied according to patients‟ diagnosis, either for FTLD patient group 
and bv-FTD variant group (Figure 2). Present findings indicate that plasma ATP levels in 
FTLD patients are significantly lower, compared to the control group (p=0.0124) and the 
same observation is valid if patients are affected with the bv-FTD variant (p=0.0161) (Figure 
2). These low extracellular ATP concentrations may reflect mitochondrial dysfunction in 
brain cells of FTLD patients.  
In spite of the limited reported data concerning mitochondrial dysfunction in FTLD, the 
implicated neuropathological mechanisms have similarities with other neurodegenerative 
disorders. In fact, different studies have also been demonstrated mitochondrial impairment 
activity in related diseases, such as AD, PD and ALS [24,26,52,84,105–110]. Additionally, our 
group has previously reported a complex I decrease in a patient with FTLD [2]. It is widely 
recognized that there is a decline of basal metabolic function and MRC activity in 
neurodegeneration [46]. This process can be potentiated by accumulation of abnormal 
intracellular or/and extracellular proteins in the affected tissues [21]. When mitochondrial 
MRC activity is impaired, ATP production is mainly derived from glycolysis [83]. However, if 
glycolytic pathway is not sufficient to provide all ATP needed to maintain cell survival, 
cytosolic ATP levels drop, which leads to a chronic bioenergetic failure [58,111]. This can be 
observed in diminished plasmatic ATP concentrations of FTLD patients in the present study 
(Figure 2).  
Moreover, the “mitochondrial cascade hypothesis” proposed for AD [46] and later in FTLD 
[2] suggests that low ATP reserves would promote tau phosphorylation in tauopathies. The 
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overexpressed and hyperphosphorylated tau, appears to impair axonal transport of 
organelles causing synapse starvation, enhance ATP depletion, and ultimately leading to 
neuronal damage in tauopathies [112]. 
In addition, intracellular ATP stores can modulate the type of cell death through apoptosis 
or necrosis [23,39]. Both these molecular pathways of cell death can occur simultaneously 
during neurodegeneration, but depending on the extent of the bioenergetics‟  failure, cell 
death will show an apoptotic or a necrotic phenotype [57]. In these situations, ATP levels 
can act as an important switch between necrosis and apoptosis and may influence the 
subsequent involved mechanisms. 
Another possible consequence of a decline in ATP production during neurodegeneration is 
the exacerbation of glutamate-induced neuroexcitotoxicity [57,67]. In fact, Del Río et al. 
(2007) [57] reported that a pathological energetic failure associated with mitochondrial 
dysfunction can exacerbate the excitotoxic neuronal injury after glutamate exposure, even at 
low concentrations. The overactivation of NMDA receptors leads to an excessive influx of 
Ca2+ to cytosol of post-synaptic neurons [40,65]. The increased cytosolic Ca2+ concentration 
will be buffered by mitochondria and endoplasmatic reticulum [113]. Consequently, high 
concentrations of Ca2+ inside mitochondrial matrix will in turn promote disturbances in 
mitochondrial membrane permeability, decreased MRC activity and ATP production that will 
enhance the bioenergetics‟ disruption, contributing to the neurodegeneration process 
[40,58,64,65]. In addition, when intracellular ATP levels drop, the mitochondria cannot 
eliminate the excess of cytosolic Ca2+ because these processes are mainly ATP-dependent 
[67]. Then, it will be acting as a positive feedback mechanism that results in mitochondrial 
Ca2+ overload and enhanced neuronal cell death.  
Although almost all FTLD patients have lower plasma ATP values compared to controls, 
some patients have extremely high ATP values. These could be a possible consequence of 
the neuroinflammation process stimulated by accumulation of dysfunctional proteins or by a 
chronic inflammation associated with other comorbidities [114–116]. Furthermore, the 
intensification of ATP release to the extracellular space have been usually related with a 
number of physiological and pathophysiological stimuli including ischemia, hypoxia, platelet 
aggregation, sympathetic nerve stimulation and cell damage that may possible interfere with 
plasma ATP content [69,78,79]. 
The evaluation of cognitive function was achieved by MMSE scale [91,92,117]. The MMSE 
criteria does not define a clinical or pathological diagnostic category, but gives some 
information about the disease severity and dementia progression of an patient [92,117]. The 
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items of the MMSE test include evaluation of orientation, registration, recall, calculation and 
attention, naming, repetition, comprehension, reading, writing and drawing [87,118]. 
However, it is important to note that MMSE evaluation for tracking disease-related cognitive 
decline in the later stages of the illness may be compromised because the scores dropped 
when patients manifested symptoms of apathy and mutism [117]. Patients‟ cognitive decline 
is usually related with an intensification of FTLD symptoms and with worse prognosis, which 
is consistent with lowered ATP values observed in patients with MMSE score “1” compared 
to control group (p=0.0026) (Figure 3). It is now generally accepted that cognitive 
impairment and language changes are due to cellular alterations, such as oxidative stress and 
low ATP production in neurons, particularly at synapses [119].  
The evaluation of dementia severity using CDR scale was also performed in 39 FTLD 
patients. The CDR scale is a clinical staging instrument that combines 6 domains of cognitive 
and functional performance: memory, orientation, judgment and problem solving, community 
affairs, home and hobbies, and personal care [90]. An algorithm allows the calculation of a 
total score, when a total score of zero reflects no dementia and higher scores denote higher 
impairment [90]. The analysis of ATP levels according to CDR score of each FTLD patient, 
showed differences between all groups (Table 1). The lowest ATP values are presented in 
patients with CDR “1” (p=0.0043) and CDR “2” (p=0.0307) comparatively to the control 
group. The ATP levels in patients with CDR “3” (p=0.7493) were higher compared to values 
observed in CDR “1” and CDR “2”, but it is important to note the limited number of cases 
with CDR “3” score. This suggests that, in the first stages of illness associated with mild 
stages of dementia (CDR “0.5”, p=0.6481), the ATP content is similar to the observed in 
controls. However, with disease progression (CDR “1” and CDR “2”), there is an 
exacerbated bioenergetics failure associated with a prominent mitochondrial dysfunction, 
probably associated to decreased ATP. Moreover, with disease progression, a subsequent 
inflammatory process can be triggered by the intracellular and extracellular accumulation of 
aggregated proteins, by signals released from the injured neurons, or by imbalances between 
pro- and anti-inflammatory processes [116,120,121]. In addition, if cell death occurs by 
apoptosis, there is no evidence of associated inflammation, but the necrotic pathway triggers 
a exacerbated inflammatory reaction [116]. Accordingly, Piguet et al. (2013) [114], reported 
that plasma levels of tumour necrosis factor (TNF), a marker of systemic inflammation, were 
significantly elevated in SD patients and in FTLD patients harbouring mutations in PGRN 
gene. The TNF expression, will in turn, induce ROS production and MRC activity decay 
[122]. 
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The disease duration analysis was performed using the cut-off at 4 years of illness, which 
correspond to half of mean disease duration reported in several epidemiological studies 
[5,95,96,123]. It is important to note that, that disease duration refereed in the present 
study corresponds to years of survival with illness until the moment of the blood collection. 
Patients with shorter duration of illness have the lowest ATP concentrations (Figure 4) 
(Table I). These results suggest that the pathological trigger that initiates the 
neurodegenerative process in FTLD may be associated with energy impairment translated 
into low ATP concentrations, but further research is needed to confirm this hypothesis. The 
higher ATP values presented in patients with longer duration of disease may be a 
consequence of an increased number of injured neurons and an augment of microglial 
activation with disease progression. When released in excess and/or for longer periods of 
time, ATP may become toxic and could contribute to neurodegeneration due to an 
activation of P2X and P2Y receptors, that will promote neuroinflammation via activation of 
P2 receptors on neurons or, indirectly, via release of pro-inflammatory cytokines from 
macrophages and/or microglia [74]. However, the analysis of ATP in cerebral spinal fluid 
would help to clarify this point.  
Patients‟ distribution according to age of onset revealed a significant difference between the 
two patients‟ groups and controls (p=0.0098 before 65 years; p=0.0044 after 65 years) 
(Table 1). This suggests that age of onset is not related ATP content. 
The female FTLD patients had significantly decreased ATP values (p=0.0276) compared to 
healthy female group (Figure 5). The vast majority of women included in patient and control 
group are in the menopause phase (patients mean age: 70±9 years; controls mean age: 
63±13 years). In menopausal women, ovarian production of estradiol is significantly 
diminished and plasma oestrogen concentration will be consequently reduced [124]. At high 
levels, oestrogens promote the expression of antioxidant molecules, and prevent initial ROS 
production induced by toxic insults [124]. In contrast, at low concentrations, oestrogens can 
stimulate disease process and will facilitate the deposition of abnormal proteins [124]. 
Although the female gender are associated with less risk of mortality in FTLD than male 
[125], the cessation of ovarian oestrogen production in postmenopausal FTLD women, 
might possibly aggravate the pathological consequences of an inherited genetic defect or a 
metabolic imbalance, contributing to disease progression [125].  
Concerning the MRC complexes‟ activities, no significant differences were observed 
between all patients and controls. However, diminished activity of complexes I, III and IV 
were identified in 6 FTLD patients, according to previously established criteria [98]. These 
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findings are consistent with other published data showing decreased activity of complexes I, 
III and IV in neurons and platelets of AD patients [24,26,49,52]. Plasma ATP values and MRC 
activities in lymphocytes were matched for each patient. A positive correlation between ATP 
values and activity of complex I (p=0.0149, Spearman r=0.3822) and a negative correlation 
between the same ATP values and the ATP synthase (Complex V) activity (p=0.0002, 
Spearman r=-0.5544) (Figure 6). These results suggest that high ATP concentrations 
correspond to an increased activity of complex I, and low ATP concentrations, correspond 
to a decreased activity of this complex. In fact, these results are in accordance with 
diminished activity of complex I and low ATP levels observed in 3 patients of the sample in 
study, according previously published criteria [98]. In addition, impairment of complex I 
activity together with decreased ATP levels are also related with presence of abnormal tau 
protein in vitro and in vivo models of tauopathies [50,126]. The abnormal function of complex 
I could enhance ROS production and upturn mtDNA mutations in the affected cells, 
contributing to the neurodegenerative process [43]. The ATP synthase activity in FTLD 
lymphocytes was similar to values obtained in control group, which are in accordance with 
data reported for AD [54].  
Nevertheless, it is quite remarkable the presence of a negative correlation between plasma 
ATP levels and ATP synthase activity in lymphocytes (p=0.0002) (Figure 6, E).  
When the MRC is inhibited, ΔΨm would decrease and prevent OXPHOS collapse, the ATP 
synthase starts to function as a proton pump and hydrolyses ATP present in the 
mitochondrial matrix [127]. Other authors reported that partial inhibition of complex I by 
rotenone can maintain ΔΨm, but collapses in the presence of oligomycin (ATP synthase 
inhibitor), clearly demonstrating the role of ATP synthase in the maintenance of ΔΨm in 
mitochondria of synaptosomes [37,67,127]. Moreover, the same effect is observed in the 
presence of the protonophore FCCP (MRC uncoupler), that collapses cellular ATP by 
reversal of ATP synthase activity. As it occurs in PD, partial inhibition of complex I is 
sufficient to reverse the activity of ATP synthase in order to stabilize ΔΨm with ATP 
hydrolysis. We hypothesize that a similar mechanism can also occurs in neuronal cells of 
FTLD patients, translated by an exacerbated activity of ATP synthase with correspondent 
plasmatic low ATP levels. In this case, glycolysis will be the major source of ATP and, as long 
as it is sufficient to maintain ΔΨm at a suboptimal level and several ATP-dependent 
functions, the cellular ATP pool is not depleted and cell survives. However, survival of cells 
with impaired MRC activity depends of their glycolytic capacity and energy demands. 
Furthermore, it has been demonstrated that ATP consumption increases dramatically when 
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cells are exposed to glutamate. In these conditions, an excess of Ca2+ influx through NMDA 
receptors would also result in collapse of the ∆Ψm, that will in turn, interrupt ATP synthesis 
and causing ATP synthase reversal activity [37,67,85]. While Ca2+ accumulation by the 
mitochondria may affect ATP synthesis, alterations in this process will in turn affect the Ca2+ 
extrusion and contribute to this pathologic mechanism and enhance the associated 
bioenergetics‟ failure [57,58].  
Our findings are original and may contribute to elucidate the important role of 
mitochondrial impairment in the complex aetiology of FTLD. Moreover, the extracellular 
ATP evaluation can also give some information about the bioenergetics‟ failure associated 
with neurodegenerative process occurring in FTLD. However, further research is required 
in order to evaluate the correlation between the plasma and cytosolic ATP concentrations in 
the compromised neurons and peripheral tissues. A more detailed characterization of the 
neuropathological mechanisms involved in FTLD would also contribute to develop future 
treatment approaches. 
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4. Conclusions 
Currently, the prevalence of neurodegenerative diseases is rising exponentially due to the 
increased lifespan, representing one of the major health problems in modern society.  
In the last years, mitochondria have been pointed as a central player in the 
neurodegeneration process that occurs in AD, PD, HD, ALS, and recently in FTLD. 
Mitochondria are responsible for producing the majority of the energy required for 
metabolic processes, essential to cell survival, and are of crucial importance in regulating cell 
death. 
The present results suggest that mitochondrial impairment in FTLD leads to a decline in ATP 
production by OXPHOS pathway, which will in turn, be reflected in decreased plasma ATP 
levels. Moreover, there is a negative correlation between plasma ATP levels and activity of 
ATP-synthase in lymphocytes of FTLD patients, due to a possible disturbance in MPTP that 
results in ion imbalance, Ca2+ overload and ultimately in ATP depletion. These findings 
support the idea that mitochondrial dysfunction and bioenergetics failure may be both the 
cause and the consequence of the neurodegeneration process that occurs in brain cells of 
FTLD patients. Additionally, since ATP may act as a signaling molecule, namely in glutamate 
release, it may play a role in neurochemical impairment occurring in neurodegeneration. 
However, more research is required to support this hypothesis and reinforce the important 
role of ATP in the neuropathological mechanisms involved in FTLD aetiology.  
These results are original and add a significant amount of data to the knowledge of 
mechanisms involved in FTLD pathogenesis, providing clues to the development of future 
therapies. 
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reproduce tables of contents or prepare lists of articles including abstracts for internal circulation 
within their institutions. Permission of the Publisher is required for resale or distribution outside the 
institution and for all other derivative works, including compilations and translations (please consult 
http://www.elsevier.com/permissions). If excerpts from other copyrighted works are included, the 
author(s) must obtain written permission from the copyright owners and credit the source(s) in the 
article. Elsevier has preprinted forms for use by authors in these cases: please consult 
http://www.elsevier.com/permissions. 
 
For Open Access articles 
Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' 
(for more information see http://www.elsevier.com/OAauthoragreement). Permitted reuse of open 
access articles is determined by the author's choice of user license (see 
http://www.elsevier.com/openaccesslicenses). 
 
Retained author rights 
As an author you (or your employer or institution) retain certain rights. For more information on 
author rights for:  
Subscription articles please see http://www.elsevier.com/authorsrights. 
Open access articles please see http://www.elsevier.com/OAauthoragreement. 
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Role of the funding source 
You are requested to identify who provided financial support for the conduct of the research and/or 
preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in 
the collection, analysis and interpretation of data; in the writing of the report; and in the decision to 
submit the article for publication. If the funding source(s) had no such involvement then this should 
be stated. Please see http://www.elsevier.com/funding. Elsevier journals comply with current NIH 
public access policy 
 
Funding body agreements and policies 
Elsevier has established agreements and developed policies to allow authors whose articles appear in 
journals published by Elsevier, to comply with potential manuscript archiving requirements as 
specified as conditions of their grant awards. To learn more about existing agreements and policies 
please visit http://www.elsevier.com/fundingbodies. 
 
Open access 
This journal offers authors a choice in publishing their research: 
Open Access 
• Articles are freely available to both subscribers and the wider public with permitted reuse 
• An Open Access publication fee is payable by authors or their research funder 
Subscription 
• Articles are made available to subscribers as well as developing countries and patient groups 
through our access programs (http://www.elsevier.com/access) 
• No Open Access publication fee 
 
All articles published Open Access will be immediately and permanently free for everyone to read 
and download. Permitted reuse is defined by your choice of one of the following Creative Commons 
user licenses: 
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create 
extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article 
(such as a translation), to include in a collective work (such as an anthology), to text or data mine the 
article, even for commercial purposes, as long as they credit the author(s), do not represent the 
author as endorsing their adaptation of the article, and do not modify the article in such a way as to 
damage the author's honour or reputation. 
Creative Commons Attribution-NonCommercial-ShareAlike (CC BY-NC-SA): for non-
commercial purposes, lets others distribute and copy the article, to create extracts, abstracts and 
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other revised versions, adaptations or derivative works of or from an article (such as a translation), 
to include in a collective work (such as an anthology), to text and data mine the article, as long as 
they credit the author(s), do not represent the author as endorsing their adaptation of the article, do 
not modify the article in such a way as to damage the author's honour or reputation, and license 
their new adaptations or creations under identical terms (CC BY-NC-SA). 
Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND): for non-
commercial purposes, lets others distribute and copy the article, and to include in a collective work 
(such as an anthology), as long as they credit the author(s) and provided they do not alter or modify 
the article. 
To provide Open Access, this journal has a publication fee which needs to be met by the authors or 
their research funders for each article published Open Access. 
Your publication choice will have no effect on the peer review process or acceptance of submitted 
articles. 
The publication fee for this journal is $3000, excluding taxes. Learn more about Elsevier's pricing 
policy: http://www.elsevier.com/openaccesspricing. 
 
Language (usage and editing services) 
Please write your text in good English (American or British usage is accepted, but not a mixture of 
these). Authors who feel their English language manuscript may require editing to eliminate possible 
grammatical or spelling errors and to conform to correct scientific English may wish to use the 
English Language Editing service available from Elsevier's WebShop 
http://webshop.elsevier.com/languageediting/ or visit our customer support site 
http://support.elsevier.com for more information. 
 
Submission 
Submission to this journal proceeds totally online and you will be guided stepwise through the 
creation and uploading of your files. The system automatically converts source files to a single PDF 
file of the article, which is used in the peer-review process. Please note that even though manuscript 
source are converted to PDF files at submission for the review process, these source files are 
needed for further processing after acceptance. All correspondence, including notification of the 
Editor's decision and requests for revision, takes place by e-mail removing the need for a paper trail. 
 
Referees 
Please submit the names, addresses, and e-mail addresses of 4 potential referees, as well as a brief 
description of their expertise relevant to your manuscript. Suggested reviewers should be individuals 
qualified to evaluate the work you have submitted. Editorial Board members who do not have 
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relevant expertise on the topic of your article should not be suggested. Please note that the 
reviewers suggested may not be current, recent or extensive collaborators of yours, and cannot have 
been involved in the preparation of the manuscript. Please note that the editor retains the sole right 
to decide whether or not the suggested reviewers are used. Failure to provide appropriate reviewer 
suggestions as noted above may result in your manuscript being returned to you without review. 
Authors may request exclusion of certain referees if conflicts of interest are anticipated. However, 
no more than 3 such names should be given. Entire groups, institutions or countries cannot be 
specified for exclusion. 
 
PREPARATION 
Use of wordprocessing software 
It is important that the file be saved in the native format of the wordprocessor used. The text should 
be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes 
will be removed and replaced on processing the article. In particular, do not use the wordprocessor's 
options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, 
superscripts etc. Please ensure that the manuscript file contains page numbers. When preparing 
tables, if you are using a table grid, use only one grid for each individual table and not a grid for each 
row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared 
in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with 
Elsevier: http://www.elsevier.com/guidepublication). Note that source files of figures, tables and text 
graphics will be required whether or not you embed your figures in the text. See also the section on 
Electronic illustrations. To avoid unnecessary errors you are strongly advised to use the "spell-check" 
and "grammar-check" functions of your wordprocessor. 
 
Article structure 
Subdivision - numbered sections 
Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 
(then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering 
also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief 
heading. Each heading should appear on its own separate line. 
Introduction  
State the objectives of the work and provide an adequate background, avoiding a detailed literature 
survey or a summary of the results. 
Material and methods 
Provide sufficient detail to allow the work to be reproduced. Methods already published should be 
indicated by a reference: only relevant modifications should be described. 
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Results 
Results should be clear and concise. 
Discussion 
This should explore the significance of the results of the work, not repeat them. A combined Results 
and Discussion section is often appropriate. Avoid extensive citations and discussion of published 
literature. 
Conclusions 
The main conclusions of the study may be presented in a short Conclusions section, which may stand 
alone or form a subsection of a Discussion or Results and Discussion section. 
Appendices 
If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in 
appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, 
Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc. 
 
Essential title page information 
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid 
abbreviations and formulae where possible. 
• Author names and affiliations. Where the family name may be ambiguous (e.g., a double name), 
please indicate this clearly. Present the authors' affiliation addresses (where the actual work was 
done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after 
the author's name and in front of the appropriate address. Provide the full postal address of each 
affiliation, including the country name and, if available, the e-mail address of each author. 
• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing 
and publication, also post-publication. Ensure that phone numbers (with country and area code) are 
provided in addition to the e-mail address and the complete postal address. Contact details must be 
kept up to date by the corresponding author. 
• Present/permanent address. If an author has moved since the work described in the article was 
done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a 
footnote to that author's name. The address at which the author actually did the work must be 
retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes. 
 
Abstract 
A concise and factual abstract is required. The abstract should state briefly the purpose of the 
research, the principal results and major conclusions. An abstract is often presented separately from 
the article, so it must be able to stand alone. For this reason, References should be avoided, but if 
essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should 
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be avoided, but if essential they must be defined at their first mention in the abstract itself. A Regular 
paper should have a Summary of 100-250 words. 
 
Graphical abstract 
A Graphical abstract is optional and should summarize the contents of the article in a concise, 
pictorial form designed to capture the attention of a wide readership online. Authors must provide 
images that clearly represent the work described in the article. Graphical abstracts should be 
submitted as a separate file in the online submission system. Image size: Please provide an image with 
a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a 
size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or 
MS Office files. See http://www.elsevier.com/graphicalabstracts for examples. Authors can make use 
of Elsevier's Illustration and Enhancement service to ensure the best presentation of their images also 
in accordance with all technical requirements: Illustration Service. 
 
Highlights 
Highlights are mandatory for this journal. They consist of a short collection of bullet points that 
convey the core findings of the article and should be submitted in a separate file in the online 
submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 
85 characters, including spaces, per bullet point). See http://www.elsevier.com/highlights for 
examples. 
 
Keywords 
Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and 
avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing 
with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords 
will be used for indexing purposes. 
 
Abbreviations 
Define abbreviations that are not standard in this field in a footnote to be placed on the first page of 
the article. Such abbreviations that are unavoidable in the abstract must be defined at their first 
mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article. 
 
Acknowledgements 
Collate acknowledgements in a separate section at the end of the article before the references and 
do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here 
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those individuals who provided help during the research (e.g., providing language help, writing 
assistance or proof reading the article, etc.). 
 
Database linking 
Elsevier encourages authors to connect articles with external databases, giving their readers oneclick 
access to relevant databases that help to build a better understanding of the described research. 
Please refer to relevant database identifiers using the following format in your article: Database: xxxx 
(e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN). See http://www.elsevier.com/databaselinking 
for more information and a full list of supported databases. 
Standards for Reporting Enzymology Data (STRENDA) 
This journal follows the recommendations of the STRENDA (Standards for Reporting Enzymology 
Data) Commission of the Beilstein-Institut for the reporting of kinetic and equilibrium binding data. 
Detailed guidelines can be found at (http://www.strenda.org/documents.html) or in this pdf file. All 
reports of kinetic and binding data must include a description of the identity of the catalytic or 
binding entity (enzyme, protein, nucleic acid or other molecule). This information should include the 
origin or source of the molecule, its purity, composition, and other characteristics such as post-
translational modifications, mutations, and any modifications made to facilitate expression or 
purification. The assay methods and exact experimental conditions of the assay must be fully 
described if it is a new assay or provided as a reference to previously published work, with or 
without modifications. The temperature, pH and pressure (if other than atmospheric) of the assay 
must always be included, even if previously published. In instances where catalytic activity or binding 
cannot be detected, an estimate of the limit of detection based on the sensitivity and error analysis of 
the assay should be provided. Ambiguous terms such as "not detectable" should be avoided. A 
description of the software used for data analysis should be included along with calculated errors for 
all parameters. First-order and second-order rate constants: see pdf for full instructions. 
 
Math formulae 
Present simple formulae in the line of normal text where possible and use the solidus (/) instead of a 
horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in 
italics. Powers of e are often more conveniently denoted by exp. Number consecutively any 
equations that have to be displayed separately from the text (if referred to explicitly in the text). 
 
Footnotes 
Footnotes should be used sparingly. Number them consecutively throughout the article, using 
superscript Arabic numbers. Many wordprocessors build footnotes into the text, and this feature 
may be used. Should this not be the case, indicate the position of footnotes in the text and present 
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the footnotes themselves separately at the end of the article. Do not include footnotes in the 
Reference list. 
Table footnotes 
Indicate each footnote in a table with a superscript lowercase letter. 
 
Artwork 
Image manipulation 
Whilst it is accepted that authors sometimes need to manipulate images for clarity, manipulation for 
purposes of deception or fraud will be seen as scientific ethical abuse and will be dealt with 
accordingly. 
For graphical images, this journal is applying the following policy: no specific feature within an image 
may be enhanced, obscured, moved, removed, or introduced. Adjustments of brightness, contrast, or 
color balance are acceptable if and as long as they do not obscure or eliminate any information 
present in the original. Nonlinear adjustments (e.g. changes to gamma settings) must be disclosed in 
the figure legend. 
Electronic artwork 
General points 
• Make sure you use uniform lettering and sizing of your original artwork. 
• Embed the used fonts if the application provides that option. 
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or 
use fonts that look similar. 
• Number the illustrations according to their sequence in the text. 
• Use a logical naming convention for your artwork files. 
• Provide captions to illustrations separately. 
• Size the illustrations close to the desired dimensions of the printed version. 
• Submit each illustration as a separate file. 
A detailed guide on electronic artwork is available on our website: 
http://www.elsevier.com/artworkinstructions 
You are urged to visit this site; some excerpts from the detailed information are given here. 
Formats 
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) 
then please supply 'as is' in the native document format. 
Regardless of the application used other than Microsoft Office, when your electronic artwork is 
finalized, please 'Save as' or convert the images to one of the following formats (note the resolution 
requirements for line drawings, halftones, and line/halftone combinations given below): 
EPS (or PDF): Vector drawings, embed all used fonts. 
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi. 
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TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi. 
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 
500 dpi. 
 
Please do not: 
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a 
low number of pixels and limited set of colors; 
• Supply files that are too low in resolution; 
• Submit graphics that are disproportionately large for the content. 
Color artwork 
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF)or MS 
Office files) and with the correct resolution. If, together with your accepted article, you submit 
usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in 
color on the Web (e.g., ScienceDirect and other sites) in addition to color reproduction in print. For 
further information on the preparation of electronic artwork, please see 
http://www.elsevier.com/artworkinstructions. 
Figure captions 
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A 
caption should comprise a brief title (not on the figure itself) and a description of the illustration. 
Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations 
used. 
 
Tables 
Number tables consecutively in accordance with their appearance in the text. Place footnotes to 
tables below the table body and indicate them with superscript lowercase letters. Avoid vertical 
rules. Be sparing in the use of tables and ensure that the data presented in tables do not duplicate 
results described elsewhere in the article. 
 
References 
Citation in text 
Please ensure that every reference cited in the text is also present in the reference list (and vice 
versa). Any references cited in the abstract must be given in full. Unpublished results and personal 
communications are not recommended in the reference list, but may be mentioned in the text. If 
these references are included in the reference list they should follow the standard reference style of 
the journal and should include a substitution of the publication date with either 'Unpublished results' 
or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been 
accepted for publication and a copy of the title page of the relevant article must be submitted. 
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Web references 
As a minimum, the full URL should be given and the date when the reference was last accessed. Any 
further information, if known (DOI, author names, dates, reference to a source publication, etc.), 
should also be given. Web references can be listed separately (e.g., after the reference list) under a 
different heading if desired, or can be included in the reference list. 
References in a special issue 
Please ensure that the words 'this issue' are added to any references in the list (and any citations in 
the text) to other articles in the same Special Issue. 
Reference management software 
This journal has standard templates available in key reference management 
packages EndNote (http://www.endnote.com/support/enstyles.asp) and Reference Manager 
(http://refman.com/support/rmstyles.asp). Using plug-ins to wordprocessing packages, authors only 
need to select the appropriate journal template when preparing their article and the list of references 
and citations to these will be formatted according to the journal style which is described below. 
Reference style 
Text: Indicate references by number(s) in square brackets in line with the text. The actual authors can 
be referred to, but the reference number(s) must always be given. 
Example: '..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result ....' 
List: Number the references (numbers in square brackets) in the list in the order in which they 
appear in the text. 
Examples: 
Reference to a journal publication: 
[1] J. van der Geer, J.A.J. Hanraads, R.A. Lupton, The art of writing a scientific article, J. Sci. Commun. 
163 (2010) 51–59. 
Reference to a book: 
[2] W. Strunk Jr., E.B. White, The Elements of Style, fourth ed., Longman, New York, 2000. 
Reference to a chapter in an edited book: 
[3] G.R. Mettam, L.B. Adams, How to prepare an electronic version of your article, in: B.S. Jones, 
R.Z. Smith (Eds.), Introduction to the Electronic Age, E-Publishing Inc., New York, 2009, pp. 281–
304. 
Journal abbreviations source 
Journal names should be abbreviated according to: 
List of title word abbreviations: http://www.issn.org/2-22661-LTWA-online.php; NLM Catalog 
(Journals referenced in the NCBI Databases): http://www.ncbi.nlm.nih.gov/nlmcatalog/journals; CAS 
(Chemical Abstracts Service): via http://www.cas.org/content/references/corejournals. 
 
Video data 
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Elsevier accepts video material and animation sequences to support and enhance your scientific 
research. Authors who have video or animation files that they wish to submit with their article are 
strongly encouraged to include links to these within the body of the article. This can be done in the 
same way as a figure or table by referring to the video or animation content and noting in the body 
text where it should be placed. All submitted files should be properly labeled so that they directly 
relate to the video file's content. In order to ensure that your video or animation material is directly 
usable, please provide the files in one of our recommended file formats with a preferred maximum 
size of 50 MB. Video and animation files supplied will be published online in the electronic version of 
your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com. Please 
supply 'stills' with your files: you can choose any frame from the video or animation or make a 
separate image. These will be used instead of standard icons and will personalize the link to your 
video data. For more detailed instructions please visit our video instruction pages at 
http://www.elsevier.com/artworkinstructions. Note: since video and animation cannot be embedded 
in the print version of the journal, please provide text for both the electronic and the print version 
for the portions of the article that refer to this content. 
 
Audio Slides 
The journal encourages authors to create an Audio Slides presentation with their published article. 
Audio Slides are brief, webinar-style presentations that are shown next to the online article on 
Science Direct. This gives authors the opportunity to summarize their research in their own words 
and to help readers understand what the paper is about. More information and examples are 
available at http://www.elsevier.com/audioslides. Authors of this journal will automatically receive an 
invitation e-mail to create an Audio Slides presentation after acceptance of their paper. 
 
Supplementary data 
Elsevier accepts electronic supplementary material to support and enhance your scientific research. 
Supplementary files offer the author additional possibilities to publish supporting applications, high-
resolution images, background datasets, sound clips and more. Supplementary files supplied will be 
published online alongside the electronic version of your article in Elsevier Web products, including 
Science Direct: http://www.sciencedirect.com. In order to ensure that your submitted material is 
directly usable, please provide the data in one of our recommended file formats. Authors should 
submit the material in electronic format together with the article and supply a concise and 
descriptive caption for each file. For more detailed instructions please visit our artwork instruction 
pages at http://www.elsevier.com/artworkinstructions. 
 
Submission checklist 
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The following list will be useful during the final checking of an article prior to sending it to the journal 
for review. Please consult this Guide for Authors for further details of any item. 
Ensure that the following items are present: 
One author has been designated as the corresponding author with contact details: 
• E-mail address 
• Full postal address 
• Phone numbers 
All necessary files have been uploaded, and contain: 
• Keywords 
• All figure captions 
• All tables (including title, description, footnotes) 
Further considerations 
• Manuscript has been 'spell-checked' and 'grammar-checked' 
• References are in the correct format for this journal 
• All references mentioned in the Reference list are cited in the text, and vice versa 
• Permission has been obtained for use of copyrighted material from other sources (including the 
Web) 
• Colour figures are clearly marked as being intended for colour reproduction on the Web (free of 
charge) and in print, or to be reproduced in colour on the Web (free of charge) and in black-and-
white in print 
• If only colour on the Web is required, black-and-white versions of the figures are also supplied for 
printing purposes 
For any further information please visit our customer support site at http://support.elsevier.com. 
 
 
AFTER ACCEPTANCE 
Use of the Digital Object Identifier 
The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI 
consists of a unique alpha-numeric character string which is assigned to a document by the publisher 
upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal 
medium for citing a document, particularly 'Articles in press' because they have not yet received their 
full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the 
journal Physics Letters B): http://dx.doi.org/10.1016/j.physletb.2010.09.059. When you use a DOI to 
create links to documents on the web, the DOIs are guaranteed never to change. 
 
Proofs 
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One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do not 
have an e-mail address then paper proofs will be sent by post) or, a link will be provided in the e-mail 
so that authors can download the files themselves. Elsevier now provides authors with PDF proofs 
which can be annotated; for this you will need to download Adobe Reader version 7 (or higher) 
available free from http://get.adobe.com/reader. Instructions on how to annotate PDF files will 
accompany the proofs (also given online). The exact system requirements are given at the Adobe 
site: http://www.adobe.com/products/reader/tech-specs.html. If you do not wish to use the PDF 
annotations function, you may list the corrections (including replies to the Query Form) and return 
them to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this 
is not possible, then mark the corrections and any other comments (including replies to the Query 
Form) on a printout of your proof and return by fax, or scan the pages and e-mail, or by post. Please 
use this proof only for checking the typesetting, editing, completeness and correctness of the text, 
tables and figures. Significant changes to the article as accepted for publication will only be considered 
at this stage with permission from the Editor. We will do everything possible to get your article 
published quickly and accurately – please let us have all your corrections within 48 hours. It is 
important to ensure that all corrections are sent back to us in one communication: please check 
carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. 
Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of 
your article if no response is received. 
 
Offprints 
The corresponding author, at no cost, will be provided with a PDF file of the article via email (the 
PDF file is a watermarked version of the published article and includes a cover sheet with the journal 
cover image and a disclaimer outlining the terms and conditions of use). For an extra charge, paper 
offprints can be ordered via the offprint order form which is sent once the article is accepted for 
publication. Both corresponding and co-authors may order offprints at any time via Elsevier's Web 
Shop (http://webshop.elsevier.com/myarticleservices/offprints). Authors requiring printed copies of 
multiple articles may use Elsevier Web Shop‟s 'Create Your Own Book' service to collate multiple 
articles within a single cover 
(http://webshop.elsevier.com/myarticleservices/offprints/myarticlesservices/booklets).  
 
 
AUTHOR INQUIRIES 
For inquiries relating to the submission of articles (including electronic submission) please visit this 
journal's homepage. For detailed instructions on the preparation of electronic artwork, please visit 
http://www.elsevier.com/artworkinstructions. Contact details for questions arising after acceptance 
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of an article, especially those relating to proofs, will be provided by the publisher. You can track 
accepted articles at http://www.elsevier.com/trackarticle. You can also check our Author FAQs at 
http://www.elsevier.com/authorFAQ and/or contact Customer Support via 
http://support.elsevier.com. 
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